SAR-441169 is under clinical development by Lead Pharma Holding and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SAR-441169’s likelihood of approval (LoA) and phase transition for Psoriasis took place on 26 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SAR-441169 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SAR-441169 is under development for the treatment of autoimmune diseases including rheumatoid arthritis, psoriasis and inflammatory bowel disease. The drug candidate is administered by oral route. The program consists of drugs that act by targeting nuclear receptor retinoic acid receptor-related orphan receptor gamma (RORgamma).
Lead Pharma Holding overview
Lead Pharma Holding (Lead Pharma) is a drug discovery company that develops, discovers, and commercializes innovative therapeutics against cancer and autoimmune diseases. The company offers products such as RORyT, ERRa, LXR, and New Target Development. Its lead product pipeline program RORyt regulates the production of pro-inflammatory protein and finds application in the therapeutic area of autoimmune diseases. The company also develops LXR. It has a collaboration with Sanofi. Lead Pharma is headquartered in Oss, the Netherlands.
Quick View SAR-441169 LOA Data
|Highest Development Stage|